ZENTALIS PHARMACEUTICALS, INC. : LEERINK PARTNERS ASSUMES COVERAGE WITH OUTPERFORM VS MARKET PERFORM RATING; TARGET PRICE $8 VS $4

Reuters · 3d ago

Please log in to view news